GlassScriptPhysician profile
Carlos Vargas
NPI 1750345757
$10,447.45
in general payments reported to CMS, 2019-2025
34 companies · $1,596 in 2025
The $1,596 reported for 2025 was more than what 92% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,011 · 2020: $1,225 · 2021: $1,997 · 2022: $1,443 · 2023: $1,348 · 2024: $826 · 2025: $1,596.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,695 · Education: $76.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,695.11 |
| Education | $76.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,423.30 | 2019-2024 | Xifaxan, Trulance |
| Abbvie INC. | $1,884.59 | 2019-2025 | Linzess, Viberzi, Rinvoq |
| Gilead Sciences, INC. | $1,001.94 | 2019-2025 | |
| Ardelyx, INC. | $722.76 | 2022-2025 | Ibsrela |
| Ferring Pharmaceuticals INC. | $635.68 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $613.95 | 2019-2024 | Linzess |
| Intercept Pharmaceuticals, INC. | $611.31 | 2019-2025 | Ocaliva |
| Ipsen Biopharmaceuticals, INC | $405.52 | 2024-2025 | Iqirvo, Bylvay |
| Nestle Healthcare Nutrition INC. | $245.54 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $233.19 | 2019-2022 | |
| Allergan, INC. | $223.80 | 2019 | |
| Janssen Biotech, INC. | $185.58 | 2023-2025 | Stelara, Tremfya, Remicade |
| Regeneron Healthcare Solutions, INC. | $153.31 | 2022-2025 | Dupixent |
| Madrigal Pharmaceuticals | $151.25 | 2025 | Rezdiffra |
| Echosens North America, INC. | $113.78 | 2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $108.21 | 2022 | |
| Celgene Corporation | $94.71 | 2021-2023 | Zeposia |
| Braintree Laboratories, INC. | $90.64 | 2019-2025 | Suflave |
| Redhill Biopharma INC. | $87.61 | 2020-2021 | |
| Mylan Specialty L.P. | $74.53 | 2022 | |
| Phathom Pharmaceuticals, INC. | $45.84 | 2023-2025 | Voquezna |
| Lilly USA, LLC | $41.39 | 2023-2025 | Omvoh |
| Genzyme Corporation | $40.36 | 2022-2025 | |
| Intra-Sana Laboratories | $37.12 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Evoke Pharma, INC. | $33.92 | 2021-2025 | |
| Celltrion USA INC. | $24.76 | 2024 | Vegzelma |
| Novo Nordisk INC | $24.42 | 2025 | Wegovy |
| Exact Sciences Corporation | $23.11 | 2025 | The Cologuard Plus Collection Kit |
| Alfasigma USA, INC. | $22.93 | 2020 | |
| Alexion Pharmaceuticals, INC. | $22.61 | 2019 | |
| Organon LLC | $19.88 | 2022 | |
| Shionogi INC | $19.71 | 2020 | |
| Concordia Pharmaceuticals INC. | $17.38 | 2019 | |
| Qol Medical, LLC | $12.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Vargas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.